In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Conmed (CNMD – Research Report), with a price target of $95.00. The company’s shares closed last Friday at $65.78.
According to TipRanks, O’Brien is a 4-star analyst with an average return of 5.5% and a 51.64% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Conmed, Dexcom, and Boston Scientific.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Conmed with a $93.43 average price target, implying a 42.03% upside from current levels. In a report released on April 25, J.P. Morgan also maintained a Buy rating on the stock with a $75.00 price target.
CNMD market cap is currently $2.03B and has a P/E ratio of 25.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Conmed (CNMD) Company Description:
CONMED Corp. operates as a medical technology company, which engages in the development, manufacture and sale of surgical devices and related equipment. It operates through the following geographical segments: United States; Americas excluding the United States; Europe, Middle East, and Africa; and Asia Pacific. Its product lines also include orthopedic surgey and general surgery. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Utica, NY.
Read More on CNMD:
